Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Maxacalcitol

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Maxacalcitol: Sponsors, patents, clinical trial progress

Maxacalcitol is an investigational drug.

There have been 4 clinical trials for Maxacalcitol. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2011.

The most common disease conditions in clinical trials are Neoplasm Metastasis, Hyperparathyroidism, Secondary, and Hyperparathyroidism. The leading clinical trial sponsors are Abbott, AbbVie (prior sponsor, Abbott), and Kumamoto University.

There are one hundred and fifty-nine US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Maxacalcitol
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismAbbVie (prior sponsor, Abbott)Phase 3
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary HyperparathyroidismAbbottPhase 2
Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving HemodialysisAbbott Japan Co.,LtdPhase 2

See all Maxacalcitol clinical trials

Clinical Trial Summary for Maxacalcitol

Top disease conditions for Maxacalcitol
Top clinical trial sponsors for Maxacalcitol

See all Maxacalcitol clinical trials

US Patents for Maxacalcitol

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Maxacalcitol   Start Trial Sprayable topical carrier and composition comprising phosphatidylcholine LIPIDOR AB (Stockholm, SE)   Start Trial
Maxacalcitol   Start Trial Combination of low dose 2-methylene-19-nor-(20S)1.alpha., 25-dihydroxyvitamin D.sub.3 and calcimimetics to treat secondary hyperparathyroidism Wisconsin Alumni Research Foundation (Madison, WI)   Start Trial
Maxacalcitol   Start Trial Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse Institut National de la Sante et de la Recherche Medicale (INSERM) (Paris, FR) Centre National de la Recherche Scientifique (C.N.R.S.) (Paris, FR) Universite Paris Descartes (Paris, FR) Foundation Imagine (Paris, FR) Universite Paris Diderot--Paris 7 (Paris, FR) Universite Paris--Sud (Orsay, FR) Assistance Publique-Hopitaux de Paris (APHP) (Paris, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.